Throughout the last three months, 13 analysts have evaluated Nurix Therapeutics (NASDAQ:NRIX), offering a diverse set of opinions from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 6 | 7 | 0 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 1 | 3 | 0 | 0 | 0 |
| 2M Ago | 2 | 3 | 0 | 0 | 0 |
| 3M Ago | 2 | 1 | 0 | 0 | 0 |
Insights from analysts' 12-month price targets are revealed, presenting an average target of $29.54, a high estimate of $36.00, and a low estimate of $20.00. This current average reflects an increase of 6.64% from the previous average price target of $27.70.
Deciphering Analyst Ratings: An In-Depth Analysis
The standing of Nurix Therapeutics among financial experts becomes clear with a thorough...
Login or create a forever free account to read this news
Sign up/Log in
